The scale of the investment at stake is considerable. Robotic surgery systems for joint replacement typically cost around one million pounds in upfront capital expenditure, with an additional estimated one thousand to two thousand five hundred pounds per patient in procedural costs. For a health service performing hundreds of thousands of hip and knee replacements each year, the difference between adopting robotics widely and continuing with conventional techniques represents a financial commitment running into billions of pounds. Against that backdrop, the researchers behind the new studies argue that their results highlight the importance of careful evaluation of robotic technology in publicly funded healthcare systems, given the substantially higher capital and procedural costs involved compared with established surgical methods.

Robotic-assisted joint replacement involves surgeons using computer-controlled robotic arms and high-definition camera systems to assist them during complex procedures. The technology is designed to help plan and execute bone cuts and implant positioning with a precision that exceeds what can be achieved freehand, and earlier studies have consistently shown that robotic assistance does improve the accuracy of implant placement. Better alignment and positioning have long been considered plausible routes to longer-lasting implants, since malpositioned components can wear unevenly, loosen, or destabilise a joint over time. If more precise surgery translated into fewer failed implants, the economics of robotics could eventually prove favourable even at a high initial price. What has remained unclear, however, is whether that theoretical chain of benefit actually holds in clinical practice.

That uncertainty prompted the National Institute for Health and Care Excellence, the body that advises the NHS on which technologies represent value for money, to call for urgent research into the effect of robotic surgery on revision risk after joint replacement. Revision surgery, in which a failed or problematic implant is replaced with a new one, is more complex, more costly, and generally associated with worse outcomes for patients than the original operation. Any technology that reliably reduced revision rates would therefore carry substantial clinical and economic value. The new studies were designed to answer precisely this question using the most comprehensive source of joint replacement data available in the United Kingdom.

The research team analysed National Joint Registry records covering 666,283 total hip replacements, of which 656,080 were performed conventionally and 10,203 robotically, and 697,145 total or partial knee replacements, of which 675,034 were conventional and 22,111 robotic. All procedures took place between 2018 and 2024 in both public and private hospitals across the UK, making this the first big data study of robotic joint replacement conducted in the country. Because patients are not randomly assigned to robotic or conventional surgery, the researchers used a statistical technique known as propensity score matching to balance out underlying differences between the two groups, allowing more reliable comparisons to be drawn from observational data.

Propensity score matching works by pairing patients who underwent robotic surgery with statistically comparable patients who had conventional operations, matching on characteristics that could independently influence outcomes. In this analysis, the factors taken into account included age, sex, body mass index, underlying diagnosis, physical fitness, implant type, and surgeon volume. By constructing balanced comparison groups in this way, the method seeks to mimic the conditions of a randomised controlled trial, an approach known as target trial emulation. The researchers note that this is one of the most robust methods available for analysing observational data, providing vital insights to help commissioners plan care when randomised evidence is not yet available.

Having constructed their matched cohorts, the researchers compared a broad range of outcomes between the robotic and conventional groups, including implant survival, patient survival, the specific reasons for revision surgery, and complications occurring during the operations themselves. Patients were followed for an average of two and a half years after surgery. The results were striking in their uniformity: there were no differences in implant survival, no differences in overall or cause-specific revision risk, and no differences in intraoperative complications between the robotic and conventional hip replacement groups, and the same pattern held for knee replacements. Nor was there any difference in patient survival between the conventional and robotic hip replacement cohorts.

There was one notable exception to the otherwise null findings. Robotic surgery was associated with a lower risk of hip revisions that may be related to implant malpositioning than conventional surgery. This result is consistent with the established finding that robotic systems improve the accuracy of component placement, and it suggests that the technology may indeed reduce the specific subset of failures attributable to imperfect positioning. However, because malpositioning accounts for only a fraction of all revision procedures, this advantage was not large enough to produce a detectable difference in overall revision rates or implant survival across the matched groups during the follow-up period.

The authors are careful to spell out the limitations of their work. These are observational studies, so no firm conclusions can be drawn about cause and effect, and other unmeasured factors could have influenced the findings despite the rigor of the matching process. The average follow-up of two and a half years is also relatively short in the context of joint implants, which are expected to last fifteen to twenty years or more in many patients, and the researchers acknowledge that this limited follow-up period may mask longer-term outcomes that could yet diverge between the two surgical approaches. Questions about patient functional outcomes, such as pain, mobility, and quality of life after surgery, also remain open, and these will be addressed in due course by the ongoing RACER clinical trials.

Even so, the immediate implications for health policy are difficult to ignore. With the NHS planning a sevenfold expansion of robotic surgery by 2035, the new evidence provides the first large-scale national test of whether that investment is justified by improved outcomes, and the answer so far is that it is not, at least for the endpoints of implant survival, revision risk, and surgical complications. The researchers conclude that the results underscore the importance of careful evaluation of robotic technology in publicly funded healthcare systems, given the substantially higher capital and procedural costs involved. Until longer-term data or the RACER trials demonstrate benefits that conventional surgery cannot match, the case for widespread adoption of robotics in hip and knee replacement remains, on this evidence, unproven.

Subject of Research: Comparison of robotic-assisted versus conventional hip and knee replacement surgery using UK National Joint Registry data

Article Title: Robotic surgery offers no clear benefit over conventional joint replacement surgery

Article References: Robotic surgery offers no clear benefit over conventional joint replacement surgery. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: robotic surgery, hip replacement, knee replacement, joint replacement, National Joint Registry, The BMJ, NHS, revision surgery, implant survival, propensity score matching, health technology assessment, surgical outcomes